Nrf2 Activators as Attractive Therapeutics for Diabetic Nephropathy
Open Access
- 17 October 2011
- journal article
- editorial
- Published by American Diabetes Association in Diabetes
- Vol. 60 (11), 2683-2684
- https://doi.org/10.2337/db11-1072
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Caffeic acid phenethyl ester-mediated Nrf2 activation and IκB kinase inhibition are involved in NFκB inhibitory effect: Structural analysis for NFκB inhibitionEuropean Journal of Pharmacology, 2010
- Chronic kidney disease: a public health priority and harbinger of premature cardiovascular diseaseJournal of Internal Medicine, 2010
- Aldosterone Antagonists for Preventing the Progression of Chronic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2009
- Activation of NF-E2–Related Factor-2 Reverses Biochemical Dysfunction of Endothelial Cells Induced by Hyperglycemia Linked to Vascular DiseaseDiabetes, 2008
- Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trialThe Lancet, 2008
- Cell Survival Responses to Environmental Stresses Via the Keap1-Nrf2-ARE PathwayAnnual Review of Pharmacology and Toxicology, 2007
- Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genesMolecular Cancer Therapeutics, 2007
- Ebselen, a Seleno-organic Antioxidant, as an ElectrophileChemical Research in Toxicology, 2006
- Extremely potent triterpenoid inducers of the phase 2 response: Correlations of protection against oxidant and inflammatory stressProceedings of the National Academy of Sciences of the United States of America, 2005
- An important function of Nrf2 in combating oxidative stress: Detoxification of acetaminophenProceedings of the National Academy of Sciences of the United States of America, 2001